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Effects of additive therapy with spironolactone on 
albuminuria in diabetes mellitus: A pilot randomized 
clinical trial 
 
Abstract 
Background: Early diagnosis of albuminuria and the prevention of its progression to 
macroalbuminuria and diabetic nephropathy are crucial. Angiotensin converting enzyme 
inhibitors (ACEIs) and antagonists of angiotensin II receptors type I (ARBs) are currently 
used as first-line treatment for albuminuria in these patients. The present study was 
conducted to assess the efficacy of addition of spironolactone to ACEIs or ARB in the 
prevention of diabetic nephropathy.  
 Methods: Sixty patients were selected from the patients who referred to a Diabetes Clinic 
in this randomized clinical trial study. The control group received enalapril and the case 
group took additive therapy with spironolactone for 12 weeks. Blood pressure, 
concentrations of creatinine and albumin in the serum and urine, urinary 
albumin/creatinine ratio, serum potassium were determined for each patient in the 
beginning of and every 4-6 weeks until the end of the study. This clinical trial was 
registered in the Iranian Registry of Clinical Trials (www.irct.ir) with registration number 
ID: IRCT201105084849N2. 
Results: There was statistically significant difference in albumin/creatinine ratio between 
the two groups (p<0.001). Albuminuria reduced more significantly in case group compared 
to control group. It was measured 66.6±26.8 mg/mmol and 45.7±19 mg/mmol in control 
and case groups, respectively. The patients did not develop any significant adverse effect 
including reduction in GFR, hyperkalemia, and hypotension.  
Conclusion: Low to moderate doses of spironolactone can augment the effect of ACEIs in 
the prevention of diabetic nephropathy.  
Keywords: Diabetic nephropathy, Albuminuria, Spironolactone, Angiotensin Converting 
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Diabetes mellitus (DM) is a common metabolic disease. It is quite common in 
Iran, too. Its prevalence has been 6.1% in females and 8% in males in 2010 and it has been 
reported by the International Diabetes Federation. The prevalence of DM in Iran is higher 
than its northern nearby countries, for instance Armenia, Azerbaijan, Turkmenistan, and 
Russia (1). Diabetic nephropathy is one of the main causes of morbidity and mortality 
among the diabetics. The emergence of albuminuria in diabetic patients denotes 
progression of the disease and is associated with higher risk of cardiovascular 
complications (2, 3). Diabetic nephropathy is the most common cause of chronic renal 
failure (3-5). It is not clearly known how prolonged hyperglycemia can involve renal cells. 
However, it is suggested that some intermediary factors (include growth factors, 
angiotensin and endothelin), hemodynamic changes in capillary circulation (increase in 
circulation or glomerular filtration and increase in glomerular capillary pressure), and 
structural changes in glomerules (glomerular cells hypertrophy, and increase in external 
matrix or growth factors), and inflammation processes may contribute this effect (6). 
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Angiotensin converting enzyme inhibitors (ACEI) and 
antagonists of angiotensin II receptors type I (ARB) may 
diminish proteinuria and help to reduce the rate of 
glomerulosclerosis (7-14). Nonetheless, several studies have 
reported that ACEIs or ARBs decrease serum aldosterone 
concentration through the inhibition of the renin angiotensin 
– aldosterone system (RAS) only for the short term and its 
level returns towards normal or near normal after some time. 
This phenomenon is referred as aldosterone escape 
phenomena (15, 16). The national Kidney Foundation 
(KDOQI) has advised ACEIs and ARBs as first-line 
treatment for diabetic patients with nephropathy. The drugs 
can lower intraglomerular and intraarterial pressure by 
means of inhibition of the RAS and in this way, they can 
hinder progression of the disease to chronic renal failure 
(17). There are a number of studies that have claimed that 
spironolactone can potentiate the effect of ACEIs and ARBs 
in the prevention of diabetic nephropathy with promising 
results (2, 4, 18).  
The present study aimed to evaluate the effect of 
enalapril alone and with spironolactone in the prevention of 
diabetic nephropathy among Iranian diabetics. 
 
 
Methods 
In this pilot clinical trial study, the patients were selected 
from the Diabetes Clinic in a university teaching hospital in 
Qazvin, Iran from December 2010 to September 2011. The 
patients were assigned to case and control groups by random 
allocation. The control group received daily enalapril 25 mg 
PO Bid for 12 weeks.  
The study group took spironolactone 25 mg PO daily for 
12 weeks, besides daily enalapril 25 mg PO Bid for 12 
weeks. Informed consent was taken from all the patients. 
The study was approved by the local Ethics Committee of 
Qazvin University of Medical Sciences. 
Sixty patients aged 18-80 years old were selected if they 
had the inclusion criteria. The inclusion criteria were 
microalbuminuria after diabetic nephropathy (DM type II) 
confirmed with 24-hours urine sample, the age between  
18-80 years, and at least 3 months treatment with ACEIs 
prior to the present study. Any patient with serum creatinine 
more than 2 mg/dl, serum potassium more than 5.5 mmol/dl, 
cardiac ejection fraction less than 35%, systolic blood 
pressure less than 90 mmHg or symptomatic hypotension, 
and any contraindication for prescription of the selected 
drugs was excluded from the study.  
Blood pressure, concentrations of creatinine and albumin 
in the serum and urine, urinary albumin/creatinine ratio, 
serum potassium concentration were determined for each 
patient in the beginning, and every 4-6 weeks until the end of 
the study. The blood pressure was measured in a controlled 
standard condition. The laboratory measurements were 
performed in the clinical laboratory of Buali Hospital, a 
university teaching hospital with standard conventional 
methods.  
Statistical analysis: The comparisons of quantitative and 
qualitative variables are calculated by mean±SD and percent 
between the two groups respectively and data was analyzed 
by a univariate test of repeated measures MANOVA to 
evaluate effect treatment.  
 
 
Results 
 Twenty nine and 31 patients were enrolled in the case 
and control groups, respectively. The patients were 45-63 
years old and their mean age was 53.07±5.05 years. The 
comparison between the main characteristics of case and 
control groups was demonstrated in table 1.  
 
Table 1. Comparison between main characteristics of 
case and control groups 
 
Variables Control (n=31) 
Mean±SD 
Case (n=29) 
Mean±SD 
Disease duration 11.16±2.84 11.15±2.94 
age 53.03±5.25 53.10±4.93 
Glomerular Filtration Rate 82.55±19.18 79.84±18.05 
Systolic blood pressure 124.19±12.85 127.24±12.50 
diastolic blood pressure 75.96±8.60 79.31±8.42 
serum creatinine 1.03±0.20 1.05±0.21 
serum potassium 4.04±0.30 4.11±0.23 
albumin/creatinine ratio 119±66.86 126.3±69.36 
 
Thirty seven patients including 17 (66.5%) in case and 20 
(64.5%) in control group were males (table 2). There was 
statistically significant difference in albumin/creatinine ratio 
between the groups, as it has been shown in table 3. Systolic 
and diastolic blood pressure and serum potassium concentration 
did not notably differ between the groups (table 4). 
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Table 2. Frequency of subjects' age based on gender 
 
Gender 
Category 
Females 
N (%) 
Males 
N (%) 
SUM 
N (%) 
1-5 0 (0) 0 (0) 0 (0) 
6-10 9 (15.3) 20 (34) 29 (48.3) 
11-15 12 (20.4) 16 (27.2) 28 (47.6) 
16-20 2 (3.4) 1 (1.7) 3 (5.1) 
Total 23 (39.1) 37 (62.9) 60 (100) 
 
 
Table 3. Comparison of albumin/creatinine and creatinine and GFR in the intervention  
and control groups  
 
Group before 
Mean±SD 
after 
Mean±SD 
F Pvalue 
albumin/creatinine 
   Intervention 
   Control 
 
126±69.3 
119±66.8 
 
59.3±48.1 
73.2±53.3 
 
12.29 
 
0.001 
Creatinine 
   Intervention 
   Control  
 
1.058±0.21 
1.034±0.2 
 
1.086±0.2 
1.051±0.1 
 
0.26 
 
0.6 
GFR 
   Intervention 
   Control 
 
79.8±18 
82.5±19.1 
 
75.6±16.3 
79.6±16.6 
 
0.47 
 
0.49 
 
 
Table 4. Comparison of systolic blood pressure, diastolic blood pressure and potassium in the  
intervention and control groups at the beginning, middle and end of the study 
 
 Group before 
Mean±SD 
End of the sixth week 
Mean±SD 
after 
Mean±SD 
F Pvalue 
Systolic blood pressure 
  Intervention 
  Control 
 
127.2±2.3 
124.1±2.2 
 
121.3±1.7 
118.5±1.6 
 
117.2±1.5 
118.2±1.5 
 
3.9 
 
0.02 
Diastolic blood pressure 
  Intervention 
  Control  
 
79.3±1.5 
75.9±1.5 
 
71.3±0.8 
7.06±0.86 
 
70.6±0.68 
70.1±0.88 
 
2.34 
 
0.1 
Potassium 
  Intervention 
  Control 
 
4.11±0.23 
4.04±0.30 
 
4.35±0.46 
4.16±0.26 
 
4.40±0.46 
4.16±0.25 
 
2.7 
 
0.07 
 
Discussion 
The current study confirmed that the addition of 
spironolactone to enalapril can boost the effect of the latter 
on the decline of albumin/creatinine ratio i.e. severity of  
 
 
albuminuria and progression of diabetic nephropathy.  
Albumin/creatinine ratio reduced 66.6±29.6 from the start of 
the study to its end in case group at the same time the 
 Caspian J Intern Med 2013; 4(2): 648-653 
Effects of additive therapy with spironolactone in Diabetes Mellitus                   651 
reduction was 45.7±19 in control group. No relationship was 
found between the rate of albuminuria and age, gender, 
duration of the disease, and race of the patients. The general 
characteristics of the patients were comparable to the studies 
of Davidson and Rossing (2, 4). 
Davidson et al. have verified that an addition of 25 mg 
spironolactone orally to ACEIs for 1 month improves 
microalbuminuria 27.2% and microalbuminuria 24.3% in 
DM type II (2). Schjoedt et al. have assessed the effects of 
addition of spironolactone to maximum permissible doses of 
ACEIs and ARBs in a double-blinded clinical trial on 21 
diabetic patients. They have concluded that spironolactone 
reduces 33% of albuminuria in case group (4). Saklayen et 
al. have studied the effect of spironolactone on proteinuria in 
patients with diabetic nephropathy. They have proposed that 
the addition of the drug to ACEIs reduces protein/creatinine 
ratio of 57%, compared to 24% in group taking placebo (18). 
Numerous authors believe that aldosterone worsens the renal 
damage through an accumulation of growth factors and 
progression of degeneration of extracellular matrix, while 
spironolactone prevents from gene expression responsible 
for the regulation of extracellular matrix in the kidney. In 
this way, it may cease the progression of albuminuria and 
glomerulosclerosis. On the other hand, the RAS system 
cannot be completely inhibited by ACEIs and ARBs due to 
aldosterone escape phenomena (15, 16). The use of 
spironolactone can prevail over this phenomenon.  The 
current clinical trial also corroborated that aldosterone 
inhibition could reduce renal damage in diabetes, even 
though the drug was used for a short 1 month duration. There 
are a few studies which have assessed other aldosterone 
inhibitors such as eplerenone for this purpose. Their results 
have been promising, too (4). 
In the present study, the recommended drug regimen 
does not adversely influence blood pressure. Moreover, no 
patients developed symptomatic or severe (systolic blood 
pressure less than 90 mmHg) hypotension during the study. 
This is in contrast with the study of Davidson and Schjoedt 
who have found significant drop in systolic blood pressure 
during their studies (2, 4).  
However, Rossing et al. and Van den Meiracker have 
reported the same results (19, 20). The suggested drug 
combination has not also considerable adverse effect on 
diastolic blood pressure. This agrees with the studies of 
saklayen and Rossing (18, 19). Van den Meiracker has found 
a minor drop in diastolic blood pressure in his patients too 
(20). Hyperkalemia is a remarkable adverse effect of 
spironolactone, particularly in renal failure, or if it is used 
with ACEIs. The changes in serum potassium concentrations 
were not statistically significant in our patients. All the 
patients had serum potassium concentration lower than 4.5 
mmol/dl. Our finding goes up against the studies of Saklayen 
et al. Bianchi et al. and Van den Meiracker et al. that have 
reported significant rise in serum potassium concentration 
after treatment with spironolactone (18, 20, 21). 
Furthermore, one from the 21 patients in the study of 
Rossing et al, and 5 from the 29 patients in the case group in 
addition to 1 from the 30 patients in the placebo group in 
study of Van den Meiracker et al. were excluded from the 
study because of hyperkalemia (19, 20). The study of 
Bianchi et al. also demonstrated 0.8 mmol/dl rise in serum 
potassium concentration after one year treatment with 
spironolactone (21). 
Glomerular filtration rate (GFR) dropped a little in both 
groups in the present study, though there was no significant 
difference between the groups. It opposes to the studies of 
Saklayen et al. and Van den Meiracker et al. who have 
reported significant fall in GFR in the control group, 
whereas, it is comparable to the study of Davidson et al. (2, 
18, 20). Bianchi et al. have reported that GFR decreased 
more prominently in the case group compared to control 
group after 1 month treatment, but the reverse occurred after 
1 year treatment (21).    
The results of the present study verify that low to 
moderate doses of spironolactone augments the effect of 
ACEIs in the prevention of diabetic nephropathy, a grave 
and quite common complication of DM, without any 
considerable side effects. It is recommended that the use of 
spironolactone is taken into account when the physicians 
visit patients with the risk of diabetic nephropathy. Further 
studies with higher doses of spironolactone or in 
combination with other ACEIs can clarify more its efficacy 
in diabetic nephropathy. 
 
 
Acknowledgments 
We would like to thank the Metabolic Diseases Research 
Center for their support. 
 
 
Funding: The present study was conducted under the 
financial support of the Metabolic Diseases Research Center, 
 Caspian J Intern Med 2013; 4(2): 648-653  
652                                Ziaee A, et al. 
Qazvin University of Medical Sciences as a thesis in 
specialist degree (graduation from residency of Internal 
Medicine).  
Conflict of Interest: The authors designate that there is no 
conflict of interest. 
 
 
References 
1. International Diabetes Federation. Diabetes Prevalence - 
Country Rankings. Availible at: http://www.allcountries. 
org/ranks/ diabetes-prevalence-country-ranks. Html. 
accessed Jan 20, 2010. 
2. Davidson MB, Wong A, Hamrahian AH, Stevens M, 
Siraj ES. Effect of spironolactone therapy on albuminuria 
in patients with type 2 diabetes treated with angiotensin-
converting enzyme inhibitors. Endocr Pract. 2008; 14: 
985-92. 
3. Shahbazian H, Shahbazian H, Feghhi M, Ehsanpour A. A 
study on the effect of dual blocked of rennin and 
angiotensin systems in contoral of diabetic nephrophaty 
in patients with type 2 diabetic patients. Jundishapour Sci 
Med J 2009; 7: 90. [In Persian] 
4. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact 
of spironolactone in diabetic nephropathy. Kidney Int 
2005; 68: 2829-36. 
5. Carey RM, Siragy HM. The intrarenal renin-angiotensin 
system and diabetic nephropathy. Trends Endocrinol 
Metab 2003; 14: 274-81. 
6. Navarro-González JF, Mora-Fernández C, Muros de 
Fuentes M, García-Pérez J. Inflammatory molecules and 
pathways in the pathogenesis of diabetic nephropathy. 
Nat Rev Nephrol.  2011; 7: 327-40.  
7. ACE Inhibitors in Diabetic Nephropathy Trialist Group. 
Should all patients with type 1 diabetes mellitus and 
microalbuminuria receive angiotensin-converting enzyme 
inhibitors? A meta-analysis of individual patient data. 
Ann Intern Med 2001; 134: 370-9. 
8. Chan JC, Ko GT, Leung DH, et al. Long-term effects of 
angiotensin-converting enzyme inhibition and metabolic 
control in hypertensive type 2 diabetic patients. Kidney 
Int 2000; 57: 590-600. 
9. Effects of ramipril on cardiovascular and microvascular 
outcomes in people with diabetes mellitus: results of the 
HOPE study and MICRO-HOPE substudy. Heart 
Outcomes Prevention Evaluation Study Investigators. 
Lancet 2000; 355: 253-9. 
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of 
losartan on renal and cardiovascular outcomes in patients 
with type 2 diabetes and nephropathy. N Engl J Med 
2001; 345: 861-9. 
11. Lewis EJ, Hunsicker LG, Clarke WR, et al.  
Renoprotective effect of the angiotensin-receptor 
antagonist irbesartan in patients with nephropathy due to 
type 2 diabetes. N Engl J Med 2001; 345: 851-60. 
12. Parving HH, Lehnert H, Brøchner-Mortensen J, et al. 
Effect of irbesartan on the development of diabetic 
nephropathy in patients with type 2 diabetes. Ugeskr 
Laeger 2001; 163: 5519-24. [In Danish] 
13. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving 
HH. Renoprotective effects of angiotensin II receptor 
blockade in type 1 diabetic patients with diabetic 
nephropathy. Kidney Int 2000; 57: 601-6. 
14. Lewis EJ. The role of angiotensin II receptor blockers in 
preventing the progression of renal disease in patients 
with type 2diabetes. Am J Hypertens 2002; 15, 123S-
128S. 
15. Mohamed RH, Abdel-Aziz HR, Abd El Motteleb DM, 
Abd El-Aziz TA. Effect of RAS inhibition on TGF-beta, 
renal function and structure in experimentally induced 
diabetic hypertensive nephropathy rats. Biomed 
Pharmacother 2009 Oct 24. 
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of 
aldosterone blockade in patients with diabetic 
nephropathy. Hypertension 2003; 41: 64-8. 
17. Kidney Disease outcomes Qudity intiative (K/DOQI). 
K/DOQI Clinical Practice Guidelines on Hypertension 
and Antihypertensive Agents in Chronic kidney Disease. 
Am J Kidney Dis 2004; 43: S1-290. 
18. Saklayen MG, Gyebi LK, Tasosa J, Yap J. Effects of 
additive therapy with spironolactone on proteinuria in 
diabetic patients already on ACE inhibitor or ARB 
therapy: results of a randomized, placebo-controlled, 
double-blind, crossover trial. J Investig Med 2008; 56: 
714-9. 
19. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, 
Parving HH. Beneficial effects of adding spironolactone 
to recommended antihypertensive treatment in diabetic 
nephropathy: a randomized, double-masked, cross-over 
study. Diabetes Care 2005; 28: 2106-12. 
20. Van den Meiracker AH, Baggen RG, Pauli S, et al.  
Spironolactone in type 2 diabetic nephropathy: Effects on 
 Caspian J Intern Med 2013; 4(2): 648-653 
Effects of additive therapy with spironolactone in Diabetes Mellitus                   653 
proteinuria, blood pressure and renal function. J 
Hypertens 2006; 24: 2285-92. 
21. Bianchi S, Bigazzi R, Campese VM. Long-term effects  
 
of spironolactone on proteinuria and kidney function in 
patients with chronic kidney disease. Kidney Int 2006; 
70: 2116-23.  
 
 
 
 
 
 
 
 
 
 
 
 
 
